AbCheck is a biotechnology company specializing in the discovery and optimization of human therapeutic antibodies. They utilize advanced technologies, including microfluidics, rabbit mass humanization, and single-copy integration site technology, to develop high-quality antibody leads tailored to specific therapeutic needs.In 2024, 

AbCheck was acquired by Ampersand Biomedicines, a Flagship Pioneering Company, to accelerate platform and product development.

AbCheck offers a range of services, including antibody discovery, optimization, and proprietary library development. Their proprietary libraries, such as the Naïve Human Antibody Library and Mass Humanized Library, enable the identification of novel, medically relevant antibodies against various targets. For more information about AbCheck and their services, you can visit their official website.